Clinical Announcement

InCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued Development

September 30, 2024 SAN FRANCISCO--(BUSINESS WIRE)--InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company announces results from the RESTORE-1 Phase 3 trial and plans for continued development. • Analysis of the results of the RESTORE-1 Phase 3 trial following its premature termination demonstrated statistically significant cardioversion of...